China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its injectable DR30206, a Category 1 biologic product, in the treatment of advanced solid tumors.
DR30206: A Promising Antibody Fusion Protein Targeting PD-L1, VEGF, and TGF-β
DR30206 is an innovative antibody fusion protein that targets PD-L1, VEGF, and TGF-β, key factors in tumor growth and immune evasion. The non-clinical research results for DR30206 have demonstrated a clear mechanism of action and a significant inhibitory effect on tumor growth, positioning it as a potential new treatment option for patients with advanced solid tumors.
Non-Clinical Safety Profile of DR30206
The non-clinical safety profile of DR30206 has been found to be favorable, with results indicating good safety. This is a crucial step in advancing the drug towards clinical trials, where its efficacy and safety will be further evaluated in human subjects. The successful completion of non-clinical studies and the subsequent NMPA approval highlight Huadong Medicine’s commitment to developing innovative therapies for cancer treatment.-Fineline Info & Tech
